2/3 of Neurologists to Prescribe Aducanumab Despite Questionable Data, Cost & Risks for SAEs

Although the clinical data associated with the recent Alzheimer’s disease drug aducanumab has challenges—the U.S. Food and Drug Administration (FDA) controversially approved the drug, and consequently, the agency is now under external investigation from the Office of Inspector General (OIG)—two-thirds of neurologists surveyed in early September disclosed that they expect to have some patients on the drug by March of next year. This is the case even considering the questionable clinical data, high cost, and adverse events associated with the studies. TrialSite reminds the entire community an Alzheimer’s disease drug was approved before aducanumab—China’s Oligomannate developed by Shanghai Greenvalley Pharmaceutical Ltd., a gut microbiota-based therapy. That investigational product is now understudying in a U.S. clinical trial.

That data originates from a survey led by Spherix Global Insight, indicating the sales outlook for the new drug looks promising. While prescriptions of the newly approved drug—the first to treat Alzheimer’s disease in many years in the U.S.—have progressed slowly. The new survey indicates that one in seven Alzheimer’s patients access the drug if neuro...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee